Articles tagged with Cancer Medication
A new study published in The Lancet found that women who underwent radiation therapy as children are more likely to experience stillbirths or baby deaths when attempting to conceive. In contrast, no increased risk was found for men exposed to similar levels of radiation. The authors suggest that uterine damage may be the primary factor...
Researchers at Tel Aviv University are developing a new clinical approach to prevent cancer recurrence after surgery by blocking stress responses. The treatment involves combining two widely available medications to boost the immune system and prevent tumor metastasis, with promising results in animal studies.
Researchers found that mice lacking MTOR in their heart muscle cells developed a fatal heart condition, highlighting the potential adverse effects of MTOR inhibitors on heart health. Deletion of 4E-BP1 improved heart function and survival, suggesting a new therapeutic strategy for improving heart function in patients with heart failure.
A meta-analysis of published evidence reveals painters are at significantly increased risk of developing bladder cancer. The risk increases with length of employment as a painter, and persists even after accounting for smoking and other risk factors.
A study found that drugs inhibiting the protein MTOR can impair heart function in patients with ongoing heart dysfunction. Additionally, researchers discovered that deleting the protein 4E-BP1 improved heart function and survival in mice. These findings suggest a potential new therapeutic strategy for improving heart health.
The largest study of its kind has released its first results, providing a wealth of information on how genetic mutations affect cancer responses to treatments. The research aims to improve patient care by tailoring treatment to individual tumour characteristics.
Researchers at Northwestern University developed a new arsenic nanoparticle that effectively targets and blocks aggressive triple negative breast cancer. The nanoparticles deliver the toxic cargo directly to tumor cells while shielding normal tissue from harm, making it a promising lead for improving chemotherapy drugs.
Long-term follow-up study reveals increased mortality rates in childhood cancer survivors due to second primary cancers and cardiac deaths. Risk persists beyond 45 years after initial diagnosis, likely attributed to late complications of treatment.
A new study has found that centralized telephone-based care management can significantly reduce pain and depression in cancer patients. The INCPAD study combined automated calls with follow-up calls from nurse care managers, and the results showed improved outcomes for patients with all types of cancers.
Researchers from the John Theurer Cancer Center have made exciting progress in elucidating the mechanisms of bortezomib in mantle cell lymphoma. The study identified biomarkers that can help guide patient selection and speed up the development of targeted cancer drugs.
A Stanford study found that arsenic trioxide can block the Hedgehog pathway, a signaling cascade involved in various cancers. The compound inhibits the expression of certain genes, making it harder for cancer cells to mutate and evade treatment.
A genetically reprogrammed herpes virus and an anti-vascular drug combination shrinks spreading distant sarcomas in mice, with significant tumor reduction and improved survival rates. Researchers achieved these results by using the virus systemically via injection, overcoming a major stumbling block in previous cancer treatments.
New research reveals that cellular changes in fat tissue, rather than the immune system, contribute to glucose intolerance and type 2 diabetes. The study found that a specific gene, protein kinase C-zeta, promotes inflammation in fat cells, leading to insulin resistance.
A new therapy called olaparib has shown promising results in slowing tumor growth in advanced breast cancer patients with a genetic mutation. The treatment was found to be effective in 85% of patients, with fewer side effects compared to traditional therapies.
Researchers developed a novel optical imaging technique called Cerenkov Luminescence Imaging (CLI) that could lead to faster development of radiopharmaceuticals. CLI harnesses the speed of light to visualize medical isotopes, overcoming current limitations in nuclear imaging modalities.
Leading stem cell researcher Irving Weissman warns of unproven treatments being marketed on the internet, putting patients at risk of harm. His organization has launched a website to educate patients and provide guidance on how to spot fraudulent clinics.
Research published in the Journal of Leukocyte Biology suggests that bortezomib induces cell death only in active and proliferating T cells, leaving resting T cells untouched. This could lead to a new treatment option for inflammatory diseases without affecting all T cells equally.
A new study found that nearly 49% of women with early-stage breast cancer did not complete their full hormone therapy regimen. Younger women were more likely to discontinue treatment. The study highlights the need for better understanding and interventions to reduce treatment non-compliance.
Researchers at the University of Leeds are developing a new cancer treatment that uses gas bubbles and sound waves to deliver toxic drugs directly to tumors. The technique has the potential to be adapted for other diseases and could provide a more effective and targeted treatment for colorectal cancer.
Scientists at Dana-Farber Cancer Institute found a way to disable MCL-1 protein, a common obstacle to chemotherapy treatment. The discovery suggests a new approach to target MCL-1 and make standard cancer drugs effective again.
A study by UC Davis researcher Joshua Fenton found that use of computer-aided detection (CAD) in mammography screenings surged after Medicare began covering its cost. The prevalence of CAD increased from 5% to 27% between 2001 and 2003, despite uncertainty over its clinical impact on breast cancer outcomes.
A new study found that 18% of U.S. cancer survivors, or over two million individuals, are not getting one or more needed medical services because of financial worries. Cancer survivors under 65 were more likely to delay or forgo all types of medical care than their peers without a history of cancer.
A recent analysis found that 18% of US cancer survivors, equating to over two million individuals, did not receive necessary medical services in the previous year due to financial worries. Cancer survivors under 65 were 55% more likely to delay or forgo all types of medical care than their non-cancer peers.
A meta-analysis of publicly available data from randomised trials found that patients taking ARBs had a significantly increased likelihood of new cancer diagnosis compared with patients in control groups. The study also found a modestly increased risk of lung cancer among ARB users, but no significant excess in cancer deaths.
Cardiologists at University Hospitals Case Medical Center have discovered a significant association between angiotensin-receptor blockers (ARBs) and an increased risk of new cancers. The meta-analysis found that patients taking ARBs had a 8-11% higher risk of developing new cancer compared to those taking control medications.
A new Tel Aviv University study found that Type 2 diabetes doubles the risk of female genital and other cancers. The study recommends screening for colon cancer earlier and more often for diabetic women to save lives.
A European survey found that up to 45% of cancer patients with breakthrough pain do not adhere to medication despite severe episodes. Patients want medications that relieve pain quickly and cause few side effects, yet current treatments often fail to meet these needs.
A study found that bevacizumab increases the risk of severe urinary protein loss by more than four-fold in patients, highlighting the need for monitoring kidney health when prescribing this cancer drug. Patients with kidney cancer or receiving high doses of bevacizumab are at greatest risk.
A phase I clinical trial of the combination of decitabine and carboplatin has shown promising results in treating late-stage ovarian cancer, with four patients experiencing no disease progression after six months. The treatment regimen has been found to be well-tolerated, with mild adverse reactions.
A new treatment regimen combining bevacizumab with standard chemotherapy significantly extends progression-free survival for women with advanced ovarian cancer, reducing disease worsening to 14.1 months compared to 10.3 months. The trial results also point to the possibility of more personalized and effective treatment in the future.
A new chemotherapy delivery method has shown promising results in treating advanced melanoma patients with liver metastasis. The phase III trial demonstrated a significant increase in progression-free survival rates and controlled tumors in the liver.
A Phase III clinical study found that dasatanib provides quicker responses and better outcomes compared to imatinib for newly diagnosed CML patients. The study reported higher rates of confirmed complete cytogenic response and major molecular response in the dasatanib arm.
Two new CML treatments, nilotinib and dasatinib, demonstrate improved efficacy over existing medications in treating drug-resistant chronic myeloid leukemia. Clinical trials showed significant increases in complete cytogenetic response and major molecular response rates compared to standard treatment.
The University of North Carolina has launched a new imaging center with advanced microscopes and equipment, providing researchers with cutting-edge technology and collaboration opportunities. The center is designed to stimulate scientific inquiry in fields such as cancer, neuroscience, and pharmacology.
Researchers at Fox Chase Cancer Center are testing a new antibody, MM-111, that targets the HER2/HER3 pathway in patients with advanced breast and gastric cancers. The trial aims to provide an additional therapeutic target within the HER2 pathway and potentially overcome resistance to current HER2-targeted therapies.
Researchers at University of Florida have developed a two-pronged therapy targeting both leukemia cells and their environment. The therapy, called Oxi4503, uses an agent that poisons leukemia cells and destroys blood vessels supplying them with oxygen and nutrients.
Researchers tested methylphenidate, a psychostimulant medication, to treat cancer-related fatigue. While the study found no significant difference between treatment and placebo groups, there was a trend of improved satisfaction with treatment among patients receiving methylphenidate, particularly those with stage III/IV cancer.
Researchers have found a key interaction between the Notch signaling system and the BCL6 gene that may be responsible for certain cancers developing. This discovery could lead to a better understanding of cancer formation and potential treatments.
A phase III clinical trial found no significant difference in overall survival between AE-941 and placebo arms for patients with non-small cell lung cancer. The study suggests that shark cartilage-derived products do not support the treatment of lung cancer.
A study published in the American Society of Clinical Oncology annual meeting showed that lenalidomide significantly improved response rates and complete remission in patients with transformed lymphoma. Patients treated with lenalidomide had a remarkable response rate, with some experiencing complete remission for over a year.
A study published in Trials highlights the widespread issue of publication bias, where favourable results are selectively published, leading to delays in implementing effective treatments. This can result in patients being prescribed futile or harmful treatments, as was the case with a drug used to prevent irregular heartbeats.
Researchers at UMass Medical School have identified a crucial pathway in malignant glioma cells that can be targeted with existing cancer drugs, offering new possibilities for therapy. The discovery was made using genome-wide RNA interference screening and has implications for the treatment of this deadly brain cancer.
Researchers at UC Berkeley have discovered a new action mechanism for topoisomerases, enzymes that uncoil DNA, which could lead to the development of more effective antibiotics and anticancer drugs. The discovery, led by James Berger, provides a better understanding of how these enzymes interact with DNA and drugs.
Researchers have found a way to tap into the properties of p53 to kill cancer cells while sparing normal cells. By controlling the cell cycle and inducing endoreduplication in cancer cells, they can target tumour-specific killing while minimizing damage to healthy cells.
Researchers have discovered a distinct gene expression pattern in kidney transplant recipients who didn't reject their transplanted kidneys despite stopping immunosuppressive therapy. The finding may help identify other transplant recipients who can safely reduce or end their use of anti-rejection drugs.
Researchers have identified a unique gene pattern in white blood cells of tolerant kidney transplant recipients, which may enable them to stop taking immunosuppressive drugs. The study found that B cell genes play a crucial role in maintaining tolerance to transplanted organs.
A nationwide study confirms the benefit of estrogen-lowering drugs before surgery for breast cancer patients. The treatment increased the likelihood that women could undergo breast-conservation surgery instead of mastectomy. After 16-week aromatase inhibitor therapy, 82% of women had successful breast-conservation surgery.
Researchers at Mayo Clinic have identified a key gene called GATA3 that is silenced in common kidney cancer, promoting its development. The discovery suggests that a combination of agents may turn the gene back on, providing a much-needed therapy for difficult-to-treat kidney cancer.
SNS-032 demonstrated safety and clinical activity in treating advanced B-cell malignancies such as chronic lymphocytic leukemia (CLL) and multiple myeloma. The drug inhibited cyclin-dependent kinases and caused apoptosis in cancer cells, showing potential anti-tumor effects.
Zoltan Takacs, a herpetologist and toxinologist, has been named National Geographic Emerging Explorer for 2010. He develops toxin-based drugs from venomous snake toxins, which have the potential to treat various diseases including cancer, circulatory disorders, and autoimmune diseases.
The American Cancer Society has awarded $50.7 million in new national research and training grants to 93 institutions across the US, with a focus on early career researchers and innovative ideas addressing various types of cancer, including prostate, endometrial, and liver cancers.
A clinical panel recommends that patients' blood pressure should be closely monitored and controlled before starting angiogenesis inhibitors for cancer treatment. Treating a patient's hypertension before treatment begins and maintaining blood pressure below 140/90 mmHg can help control this side effect.
Researchers discovered that metformin disables the mTOR complex through RAG GTPase, rather than activating TSC proteins via AMPK. This finding raises the possibility of using metformin more widely to treat cancer and diseases linked to TSC deficiency.
Researchers found that common steroid medications can promote and protect stem cell populations, which perform tissue repair. The study suggests potential new roles for these drugs in treating conditions such as spinal cord injury, Parkinson's disease, and improving wound healing.
A recent study by American Academy of Pediatrics found that parents administering medication to children with chronic conditions often make mistakes. The researchers visited the homes of 83 children and reviewed 544 medications, discovering 128 errors, including those that could injure the child.
A new blood test has been found to identify patients with advanced non-small-cell lung cancer who are more likely to respond to erlotinib treatment. The test, which analyzes specific 'fingerprints' of a protein called EGFR, showed a significant response rate in patients with good proteomic profiles compared to those with poor profiles.
A study finds that cancer risk in kidney transplant recipients is similar across different immunosuppressive medications, suggesting no single medication is to blame. Patient characteristics such as age and eye color are associated with increased cancer risk.
A significant study found that no single immunosuppressive drug regimen increases the risk of cancer among kidney transplant patients. However, factors such as age and smoking history contribute to increased cancer risk.
Researchers have developed fluorescent compounds that can light up tumors as they begin to form, signaling their transition to aggressive cancers. These compounds, called fluorocoxibs, could be used for early tumor detection, monitoring cancer progression, and defining tumor margins during surgery.
Almost 50% of AIDS patients died from AIDS, but non-AIDS related deaths increased after four years of treatment with ART. Lifestyle-related causes like suicide and liver disease were common non-AIDS deaths.